Audit Report Correction: Qualified Opinion, Adverse Internal Control, Fraud Disclosure


  • Audit opinion downgraded from unqualified to qualified due to scope limitation
  • Internal accounting control system opinion changed to adverse
  • Embezzlement/breach of trust disclosed in audit report
  • Current financials: Total assets 114,973M KRW, liabilities 75,171M KRW, equity 39,802M KRW (capital erosion ratio -52.5%)
  • Revenue 88,594M KRW, operating profit 596M KRW, net loss 2,074M KRW (continued net loss vs prior year)
  • Capital stock 26,101M KRW vs equity 39,802M KRW (no capital impairment but debt ratio 188.8%)
  • Audit report receipt date: 2026-04-30 (overdue)
ADVERTISEMENT (250px+)

KOSPI Filing Information


  • Filing: [Correction of Description] Audit Report Submission
  • Company: Dongsung Pharmaceutical (002210)
  • Submission: Dongsung Pharmaceutical Co., Ltd.
  • Receipt: 04-30-2026
  • Under KRX KOSPI Market Division